Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 52-week multicenter, open-label, randomized, parallel, two - arm study comparing Exubera (inhaled human insulin) vs. Humalog (insulin lispro), both in combination with insulin glargine in subjects with type 1 diabetes mellitus

Next Previous
Trial Profile

A 52-week multicenter, open-label, randomized, parallel, two - arm study comparing Exubera (inhaled human insulin) vs. Humalog (insulin lispro), both in combination with insulin glargine in subjects with type 1 diabetes mellitus

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin (Primary) ; Insulin glargine; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Pfizer

Most Recent Events

  • 03 Apr 2022 Trial has been completed in Netherland (End Date: 30 Jun 2008), according to European Clinical Trials Database record.
  • 18 Aug 2009 Actual patient number changed from 86 to 58 as reported by ClinicalTrials.gov.
  • 07 Oct 2008 Planned end date changed from 1 Jan 2009 to 1 Jun 2008 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top